Dr. Markey C. Mcnutt II, MD
Medical Genetics (Clinical Genetics (M.D.) Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 66
Licensed in Texas since 2012, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of Texas Southwestern Medical School at Dallas
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical Genetics (M.D.) Physician primary
TX license P2898 (first issued 2012; active) -
Endocrinology, Diabetes & Metabolism Physician
TX license P2898 (first issued 2012; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ut of Texas Southwestern University Hospital - William P. Clements Jr. Dallas, TX
- Parkland Health & Hospital System Dallas, TX
Medical groups
- University of Texas Southwestern Medical Center at Dallas (3,187 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 66
- Services billed
- 82
- Patients’ average age
- 58
| Service | Times | Patients |
|---|---|---|
| New patient office or other outpatient visit, 45-59 minutes | 21 | 21 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 19 | 19 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ravicti (glycerol phenylbutyrate) | 41 |
| Palynziq (pegvaliase-pqpz) | 31 |
| Sodium Chloride (0.9 % sodium chloride) Other prescribers in Dallas, TX | 17 |
| Sodium Phenylbutyrate | 15 |
| Cerdelga (eliglustat tartrate) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 37 payments worth $146,763 in total to this clinician.
| Ultragenyx Pharmaceutical Inc. | $128,263 |
|---|---|
| BioMarin Pharmaceutical Inc. | $9,661 |
| Amicus Therapeutics, Inc. | $3,648 |
| Mirum Pharmaceuticals, Inc. | $1,625 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,456 |
| Ptc Therapeutics, Inc. | $1,028 |
| Amgen Inc. | $858 |
| Eton Pharmaceuticals, Inc. | $112 |
| Consulting Fee | $144,812 |
|---|---|
| Travel and Lodging | $1,127 |
| Food and Beverage | $824 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ultragenyx Pharmaceutical Inc. Apr 1, 2025 | Consulting Fee | $27,300 |
| Ultragenyx Pharmaceutical Inc. Jul 1, 2025 | Consulting Fee | $26,600 |
| Ultragenyx Pharmaceutical Inc. Mar 2, 2025 | Consulting Fee | $25,900 |
| Ultragenyx Pharmaceutical Inc. Jun 2, 2025 | Consulting Fee | $24,500 |
| Ultragenyx Pharmaceutical Inc. Nov 17, 2025 | Consulting Fee | $23,800 |
| Amicus Therapeutics, Inc. May 14, 2025 | Consulting Fee POMBILITI; OPFOLDA · POMPE DISEASE | $3,648 |
| Mirum Pharmaceuticals, Inc. Jul 30, 2025 | Consulting Fee CTEXLI · Rare Disease | $1,625 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
All 19 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| Ultragenyx Pharmaceutical Inc. Nov 17, 2025 | Consulting Fee | $23,800 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 3, 2025 | Travel and Lodging travel to DENVER, CO · in-kind | $51.97 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 2, 2025 | Travel and Lodging travel to DENVER, CO · in-kind | $600 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 2, 2025 | Travel and Lodging travel to DENVER, CO · in-kind | $475 |
| Ptc Therapeutics, Inc. Sep 25, 2025 | Consulting Fee | $1,000 |
| Mirum Pharmaceuticals, Inc. Jul 30, 2025 | Consulting Fee CTEXLI · Rare Disease | $1,625 |
| Ultragenyx Pharmaceutical Inc. Jul 1, 2025 | Consulting Fee | $26,600 |
| Amgen Inc. Jun 10, 2025 | Consulting Fee RAVICTI · Metabolic Disorders/Rare Disease | $858 |
| Ultragenyx Pharmaceutical Inc. Jun 2, 2025 | Consulting Fee | $24,500 |
| Amicus Therapeutics, Inc. May 14, 2025 | Consulting Fee POMBILITI; OPFOLDA · POMPE DISEASE | $3,648 |
| Ultragenyx Pharmaceutical Inc. Apr 1, 2025 | Consulting Fee | $27,300 |
| Ultragenyx Pharmaceutical Inc. Mar 2, 2025 | Consulting Fee | $25,900 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $39,611 in research payments for these studies, mostly to the institutions running them.
- Phase 3 Study of Pegtibatinase in patients with homocystinuria
Travere Therapeutics, Inc. - BMN 165-501
BioMarin Pharmaceutical Inc. - A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria
ModernaTX, Inc. · Withdrawn · NCT06147856 - BMN 165-503
BioMarin Pharmaceutical Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.